Article
Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan.
Japanese journal of clinical oncology - 1 Dec 2016
Yamane Yuki, Shiono Ayako, Ishii Yoshiki, Isobe Kazutoshi, Miyauchi Eisaku, Kishi Kazuma, Nishino Makoto, Sugawara Shunichi, Ko Ryo, Koyama Nobuyuki, Yabuki Yutaka, Kobayashi Kunihiko
Abstract excerpt
BACKGROUND: The epidermal growth factor receptor (EGFR) T790M mutation is considered the major mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) patients with EGFR-sensitizing mutations. Although chemotherapy is commonly used for those patients under the condition without T790M-targeted therapy, the clinical outcomes are poorly defined....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.